QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.108.046854v1 74/6/1533    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kleuser, B. Articles by Potteck, H. Search for Related Content PubMed PubMed Citation Articles by Kleuser, B. Articles by Potteck, H.

17-β-Estradiol Inhibits Transforming Growth Factor-β Signaling and Function in Breast Cancer Cells via Activation of Extracellular Signal-Regulated Kinase through the G Protein-Coupled Receptor 30

Institute of Pharmacy, Pharmacology and Toxicology, Freie Universität Berlin, Berlin, Germany (B.K., H.P.); Institute of Pharmacy, Pharmaceutical Biology, Freie Universität Berlin, Berlin, Germany (H.H.P.); and Institute of Pharmacy, Pharmaceutical Chemistry, Freie Universität Berlin, Berlin, Germany (D.M., R.G.)

Breast cancer development and breast cancer progression involves the deregulation of growth factors leading to uncontrolled cellular proliferation, invasion and metastasis. Transforming growth factor (TGF)-β plays a crucial role in breast cancer because it has the potential to act as either a tumor suppressor or a pro-oncogenic chemokine. A cross-communication between the TGF-β signaling network and estrogens has been postulated, which is important for breast tumorigenesis. Here, we provide evidence that inhibition of TGF-β signaling is associated with a rapid estrogen-dependent nongenomic action. Moreover, we were able to demonstrate that estrogens disrupt the TGF-β signaling network as well as TGF-β functions in breast cancer cells via the G protein-coupled receptor 30 (GPR30). Silencing of GPR30 in MCF-7 cells completely reduced the ability of 17-β-estradiol (E2) to inhibit the TGF-β pathway. Likewise, in GPR30-deficient MDA-MB-231 breast cancer cells, E2 achieved the ability to suppress TGF-β signaling only after transfection with GPR30-encoding plasmids. It is most interesting that the antiestrogen fulvestrant (ICI 182,780), which possesses agonistic activity at the GPR30, also diminished TGF-β signaling. Further experiments attempted to characterize the molecular mechanism by which activated GPR30 inhibits the TGF-β pathway. Our results indicate that GPR30 induces the stimulation of the mitogen-activated protein kinases (MAPKs), which interferes with the activation of Smad proteins. Inhibition of MAPK activity prevented the ability of E2 from suppressing TGF-β signaling. These findings are of great clinical relevance, because down-regulation of TGF-β signaling is associated with the development of breast cancer resistance in response to antiestrogens.

Address correspondence to: Dr. Burkhard Kleuser, Institute of Pharmacy, Pharmacology and Toxicology, Freie Universität Berlin, Königin-Luise-Str. 2 + 4, D-14195 Berlin, Germany. E-mail: kleuser{at}zedat.fu-berlin.de

This article has been cited by other articles:

				C. N. Harvey, M. Esmail, Q. Wang, A. I. Brooks, R. Zachow, and M. Uzumcu Effect of the Methoxychlor Metabolite HPTE on the Rat Ovarian Granulosa Cell Transcriptome In Vitro Toxicol. Sci., July 1, 2009; 110(1): 95 - 106. [Abstract] [Full Text] [PDF]

				E. R. Levin G Protein-Coupled Receptor 30: Estrogen Receptor or Collaborator? Endocrinology, April 1, 2009; 150(4): 1563 - 1565. [Full Text] [PDF]

				E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G. C. Brailoiu, X. Gao, L. Mueller-Guerre, N. A. Marjon, A. Gut, R. Minotti, et al. Regulatory Role of G Protein-Coupled Estrogen Receptor for Vascular Function and Obesity Circ. Res., February 13, 2009; 104(3): 288 - 291. [Abstract] [Full Text] [PDF]